Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Mikhail Eydelman, Senior Vice President and General Counsel at Vaxcyte, Inc. (NASDAQ:PCVX), a company currently valued at $10.9 billion, recently executed several stock transactions, according to a filing with the Securities and Exchange Commission. On February 5, Eydelman sold a total of 5,000 shares of Vaxcyte common stock, generating proceeds of approximately $450,368. The shares were sold at prices ranging from $87.767 to $91.708 per share, amid a strong six-month rally that has seen the stock surge over 26%. According to InvestingPro data, analysts maintain a highly bullish outlook with price targets ranging from $135 to $163.
Additionally, Eydelman exercised options to acquire 5,000 shares at a price of $21.41, totaling $107,050. Following these transactions, Eydelman holds 28,222 shares of Vaxcyte common stock. These sales were conducted under a Rule 10b5-1 trading plan, established on June 11, 2024. The company maintains a strong financial position with a current ratio of 17.88, indicating robust liquidity. Want deeper insights into insider trading patterns and financial health metrics? Unlock more with InvestingPro, which offers 7 additional key insights about Vaxcyte.
In other recent news, Vaxcyte, a vaccine innovation company, has made significant strides in its vaccine development. The company’s pneumococcal conjugate vaccine candidate, VAX-31, has advanced to the final stage of its Phase 2 study in infants. This progress follows a review of Stage 1 safety and tolerability data, with the next stage focusing on further evaluation of the vaccine’s safety, tolerability, and immunogenicity. The company anticipates releasing topline data from this stage in mid-2026.
In addition, the U.S. Food and Drug Administration has cleared the Investigational New Drug application for VAX-31 in infants and granted Breakthrough Therapy designation for its use in adults. These developments are a result of positive results from earlier Phase 1/2 studies.
Furthermore, Goldman Sachs has initiated coverage on Vaxcyte with a Buy rating, citing the company’s strong clinical data for its lead programs as a key driver for the positive outlook. The firm sees potential for significant global commercial opportunities for Vaxcyte, particularly with the upcoming data for VAX-24 in the infant/pediatric population expected in the first quarter of 2025.
In other company news, Vaxcyte has expanded its corporate headquarters in San Carlos, California, by entering into an amended and restated lease agreement. This expansion reflects the company’s growth and ongoing commitment to its operations and research in the field of biological products. These are the latest developments in Vaxcyte’s mission to develop vaccines aimed at protecting against bacterial diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.